296 related articles for article (PubMed ID: 14730625)
1. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice.
Li P; Schwarz EM; O'Keefe RJ; Ma L; Looney RJ; Ritchlin CT; Boyce BF; Xing L
Arthritis Rheum; 2004 Jan; 50(1):265-76. PubMed ID: 14730625
[TBL] [Abstract][Full Text] [Related]
2. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.
Li P; Schwarz EM; O'Keefe RJ; Ma L; Boyce BF; Xing L
J Bone Miner Res; 2004 Feb; 19(2):207-13. PubMed ID: 14969390
[TBL] [Abstract][Full Text] [Related]
3. Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-gamma receptor by triggering tumor necrosis factor alpha-driven osteoclastogenesis.
Geboes L; De Klerck B; Van Balen M; Kelchtermans H; Mitera T; Boon L; De Wolf-Peeters C; Matthys P
Arthritis Rheum; 2007 Aug; 56(8):2595-607. PubMed ID: 17665444
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression.
Yao Z; Li P; Zhang Q; Schwarz EM; Keng P; Arbini A; Boyce BF; Xing L
J Biol Chem; 2006 Apr; 281(17):11846-55. PubMed ID: 16461346
[TBL] [Abstract][Full Text] [Related]
7. Autoimmunity and bone.
Schwarz EM; Looney RJ; Drissi MH; O'Keefe RJ; Boyce BF; Xing L; Ritchlin CT
Ann N Y Acad Sci; 2006 Apr; 1068():275-83. PubMed ID: 16831928
[TBL] [Abstract][Full Text] [Related]
8. Osteoclast precursors, RANKL/RANK, and immunology.
Xing L; Schwarz EM; Boyce BF
Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
Binder NB; Puchner A; Niederreiter B; Hayer S; Leiss H; Blüml S; Kreindl R; Smolen JS; Redlich K
Arthritis Rheum; 2013 Mar; 65(3):608-17. PubMed ID: 23280418
[TBL] [Abstract][Full Text] [Related]
10. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
[TBL] [Abstract][Full Text] [Related]
12. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis.
Blüml S; Binder NB; Niederreiter B; Polzer K; Hayer S; Tauber S; Schett G; Scheinecker C; Kollias G; Selzer E; Bilban M; Smolen JS; Superti-Furga G; Redlich K
Arthritis Rheum; 2010 Jun; 62(6):1608-19. PubMed ID: 20155834
[TBL] [Abstract][Full Text] [Related]
13. TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood.
Zhang Q; Guo R; Schwarz EM; Boyce BF; Xing L
Arthritis Res Ther; 2008; 10(2):R37. PubMed ID: 18371213
[TBL] [Abstract][Full Text] [Related]
14. RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways.
Nakao A; Fukushima H; Kajiya H; Ozeki S; Okabe K
Biochem Biophys Res Commun; 2007 Jun; 357(4):945-50. PubMed ID: 17467668
[TBL] [Abstract][Full Text] [Related]
15. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.
Abu-Amer Y; Abbas S; Hirayama T
J Cell Biochem; 2004 Nov; 93(5):980-9. PubMed ID: 15389885
[TBL] [Abstract][Full Text] [Related]
16. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease.
Boyce BF; Schwarz EM; Xing L
Curr Opin Rheumatol; 2006 Jul; 18(4):427-32. PubMed ID: 16763465
[TBL] [Abstract][Full Text] [Related]
17. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.
Anandarajah AP; Schwarz EM; Totterman S; Monu J; Feng CY; Shao T; Haas-Smith SA; Ritchlin CT
Ann Rheum Dis; 2008 Mar; 67(3):296-301. PubMed ID: 17967829
[TBL] [Abstract][Full Text] [Related]
18. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha.
Edwards CK; Bendele AM; Reznikov LI; Fantuzzi G; Chlipala ES; Li L; Moldawer LL; Mountz JD; Li YY; Dinarello CA
Arthritis Rheum; 2006 Sep; 54(9):2872-85. PubMed ID: 16947419
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T cells protect from local and systemic bone destruction in arthritis.
Zaiss MM; Frey B; Hess A; Zwerina J; Luther J; Nimmerjahn F; Engelke K; Kollias G; Hünig T; Schett G; David JP
J Immunol; 2010 Jun; 184(12):7238-46. PubMed ID: 20483756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
